Related Insights
One Big Beautiful Bill Act: How US Tax Policy Is Reshaping Chemical Industry Investment in 2026
The H.R.1 One Big Beautiful Bill Act has become an important factor influencing capital allocation across the US chemical industry. Procurement teams, investors and manufacturers should understand how tax policy can affect production capacity, supply chains and long-term sourcing decisions.
PFAS in Consumer Products: What Eleven Days Remaining on the Comment Deadline Means
With eleven days remaining before the EPA's PFAS written comment deadline, companies that manufacture or sell PFAS-containing consumer products still have an opportunity to provide technical and commercial evidence. This guide explains why substantive, data-driven submissions can play an important role in the rulemaking process.
CSRD and Chemical Supply Chain Due Diligence: How Ownership Transfers Affect Scope 3 Data
Supplier ownership changes can create unexpected challenges for Scope 3 emissions reporting under the Corporate Sustainability Reporting Directive. This guide explains how procurement and sustainability teams should manage supplier data continuity following ownership transfers.
PFAS Post-Hearing: Building Your July 20 Comment Strategy
The EPA's PFAS public hearing has concluded, but the written comment period remains open until July 20. For chemical procurement professionals, well-supported written submissions can have a greater influence on the rulemaking record than hearing testimony alone.
PFAS EPA Hearings One Week Away: Commercial Stakes for Specialty Chemical Formulators
The upcoming EPA PFAS hearings could reshape sourcing decisions for specialty chemical formulators across the United States. Procurement teams should prepare for changing compliance requirements, evolving customer expectations and a more complex regulatory landscape.
Pharmaceutical Excipient SVHC Watch: What ECHA's July Update Means for Excipient Compliance
ECHA's upcoming SVHC candidate list update could introduce new compliance obligations for pharmaceutical excipient supply chains. Procurement and regulatory teams should prepare monitoring procedures to identify affected substances as soon as new candidate entries are published.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.